Director, Commercial Development – empasiprubart

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.

We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. 

About argenx

argenx is a global immunology company developing innovative therapies to improve the lives of people living with severe autoimmune diseases. With teams across the US, Europe, Japan, and emerging markets, we are united by our values of co‑creation, empowerment, humility, innovation, and excellence. We are expanding our therapeutic footprint across neuromuscular, hematology, dermatology, and nephrology and remain deeply committed to delivering science‑based, patient‑focused innovation. 

As empasiprubart advances through Phase 3 development across multiple rare neuromuscular and autoimmune indications, we are strengthening our global Commercial Development team with a Director who will help shape the asset’s value, strategy, and path to global launches.

The Opportunity

The Director, Commercial Development – empasiprubart will play a central role in guiding the commercialization strategy for one of argenx’s next major assets. This leader will be accountable for strategic assessments, pipeline indication value analyses, cross‑functional integration, early launch shaping, and ensuring the asset is positioned for optimal success across markets.

You will partner closely with the Complement Asset Strategy Team (COAST), Corporate Strategy, Clinical Science, Medical Affairs, Market Access, HEOR, Regulatory, CMC, Clinical Operations, and regional commercial teams—supporting the work of the Indication Development Teams (IDTs) for empasiprubart. 

This is an ideal role for someone who excels in building commercial strategy early, leading through influence, and working across ambiguity.

Location: US or Europe (Ghent/Boston/Switzerland preferred; other locations considered)

Key Responsibilities:

Commercial Strategy & Asset Leadership

• Support the development and refinement of the global commercial strategy for empasiprubart across current and future pipeline indications, in alignment with argenx Vision 2030

• Lead commercial insights generation, including opportunity assessments, competitive analysis, patient journey mapping, and indication prioritization

• Contribute to Target Product Profile (TPP) development and payer testing efforts, aligned with activities referenced in empasiprubart workstreams (e.g., TPP payer testing) to inform pricing and global access strategy

Cross‑Functional Leadership

• Serve as a key commercial partner within the empasiprubart Indication Development Teams (IDTs), ensuring integration of commercial perspectives into clinical, regulatory, HEOR, and medical plans

• Partner with the Global Launch Leads to create a seamless transition from strategic planning into launch execution

• Collaborate with Market Access, HEOR, and Pricing to ensure evidence‑generation plans meet payer expectations globally

Launch Readiness & Early Commercial Activities

• Shape pre‑launch activities including disease education, early access strategy planning, stakeholder mapping, and channel strategy

• Support brand strategy foundations including positioning, segmentation, messaging frameworks, and early creative territory exploration

• Contribute to global forecast models and scenario planning, in partnership with Commercial Insights and FP&A

External Engagement & Insight Generation

• Engage with key external stakeholders (KOLs, patient advocacy, payers, partners) to gather deep insights that influence strategic decision‑making

• Represent Commercial in business development evaluations of opportunities relevant to empasiprubart’s lifecycle

Organizational Development & Ways of Working

• Help build and scale the commercial development function within the empasiprubart franchise

• Role‑model argenx values and reinforce cross‑functional collaboration, contributing to a high‑performance,